Corvus Pharmaceuticals Inc buy melinda
Start price
26.04.18
/
50%
€8.85
Target price
26.04.18
€9.92
Performance (%)
0.00%
End price
26.04.18
€8.85
Summary
This prediction ended on 26.04.18 with a price of €8.85. The BUY prediction by melinda closed unchanged from the start price. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Corvus Pharmaceuticals Inc | 14.286% | 14.286% | 146.707% | 92.523% |
iShares Core DAX® | -0.168% | 4.802% | 17.488% | 17.061% |
iShares Nasdaq 100 | 2.946% | 3.520% | 23.619% | 36.065% |
iShares Nikkei 225® | 1.319% | 6.746% | 12.949% | 0.580% |
iShares S&P 500 | 2.044% | 3.551% | 23.055% | 39.407% |
Comments by melinda for this prediction
In the thread Corvus Pharmaceuticals Inc diskutieren
SektorBiotechnologische und medizinische Forschung
Corvus Pharmaceuticals gibt den Start der klinischen Phase 1 / 1b-Studie des experimentellen Anti-CD73-Antikörpers CPI-006 bei Patienten mit fortgeschrittenem Krebs bekannt
In einer dreiarmigen Studie wird CPI-006 als Monotherapie in Kombination mit dem Adenosinantagonisten CPI-444 und in Kombination mit Pembrolizumab untersucht
(Vom Mitglied beendet)
Stopped prediction by melinda for Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€8.88
26.04.18
26.04.18
€9.92
21.05.18
21.05.18
13.06%
21.05.18
21.05.18
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€8.02
04.03.18
04.03.18
€10.10
12.03.18
12.03.18
10.91%
12.03.18
12.03.18